Splenectomy as an effective debulking therapy for disseminated mould infection in acute myeloid leukaemia following adjuvant therapy with interferon gamma and liposomal amphotericin

Abstract

Invasive fungal infection is a major cause of morbidity and mortality in patients receiving treatment for Acute Myeloid Leukaemia (AML). Herein, we report a case of a 21 year old woman with an extremely resistant Fusarium species that responded to the addition of interferon gamma to her medical therapy, subsequently allowing definitive debulking surgery of her invasive Fusarium infection to be undertaken.

Skin and subcutaneous mycoses in tilapia (Oreochromis niloticus) caused by Fusarium oxysporum in coinfection with Aeromonas hydrophila

“…Fusarium is a large genus that belongs to the Ascomycota phylum and comprises a few hundred species that are mainly distributed in soils and in water systems [1,3] . Fusarium solani , F. oxysporum and F. verticillioides have been reported as the most frequent species causing invasive fusariosis in humans, especially in immunocompromised patients [4,16,17] . Immunocompetent individuals can be also affected, but in these patients, Fusarium usually causes localized infections.…”

Successful management of disseminated Fusarium infection in a patient with acute myeloid leukemia

“…Therapeutic options that are available for the treatment of infections caused by Fusarium sp. include: (1) single antifungal agents including: amphotericin-B, voriconazole, posaconazole and itraconazole; (2) combination therapies including either two antifungal agents such as voriconazole + amphotericin-B, voriconazole + terbina ine, caspofungin + amphotericn-B or amphotericin-B + terbina ine; or one antifungal drug + one non-antimycotic agent such as: voriconazole + metronidazole, and liposomal amphotericin-B + cipro loxacin or ibuprofen; (3) adjunctive therapies such as: surgical debridement of infected tissues, debulking surgery such as splenectomy, removal of infected or colonized CVCs, interferon-γ, G-CSF, and granulocyte transfusions; and (4) new agents such as: MGCD290 and isavaconazole [2,4,[6][7][8][9][10][11]14,[18][19][20][34][35][36]. In severely immunocompromised patients who are at high-risk of having DFIs, antifungal prophylaxis is indicated [14,15].…”